Trial Profile

A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LAT 8881 (Primary)
Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
Focus Therapeutic Use
Sponsors Lateral Pharma Pty Ltd

Most Recent Events

02 Sep 2020 Status changed from active, no longer recruiting to completed.
16 Apr 2020 Planned End Date changed from 1 May 2020 to 3 May 2020.
16 Apr 2020 Planned primary completion date changed from 1 Mar 2020 to 19 Apr 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com